Can One Molecule Target Multiple Disease Markers?

In a recent study published in Biochemical Society Transactions, researchers explored multispecific nanobody technology. This breakthrough approach enhances targeted therapy by simultaneously allowing a single molecule to bind to multiple epitopes or antigens. Unlike traditional antibodies, multispecific nanobodies offer superior stability, specificity, and therapeutic potential in cancer and viral infections.

Key Findings from the Research:

• Multispecific Targeting: These nanobodies can bind two or more targets simultaneously, improving therapeutic efficiency.
• Overcoming Tumor Heterogeneity: Cancer cells evolve rapidly, making single-target therapies less effective.
• Multispecific nanobodies tackle this challenge by blocking multiple pathways involved in tumour progression.
• Fighting Drug Resistance: Many pathogens and cancer cells develop resistance to single-target drugs. Multispecific nanobodies reduce resistance risks by neutralizing multiple variants of the same disease marker.
• Better Drug Delivery & Lower Toxicity: Their small size (~15 kDa) allows for better tissue penetration while minimizing off-target effects, reducing side effects compared to traditional antibodies.

Key Applications of Multispecific Nanobody Therapies

• Cancer Immunotherapy – Enhancing tumour targeting by binding tumour markers and immune checkpoints.
• Viral Neutralization – Targeting multiple variants of viruses like SARS-CoV-2 or influenza.
• Autoimmune Disorders – Blocking two different inflammatory mediators to prevent excessive immune activation.

Multispecific nanobody engineering, combined with high-throughput screening and computational modelling, is shaping the next generation of precision medicine.

📖 Read the full study here:

https://portlandpress.com/biochemsoctrans/article/doi/10.1042/BST20241419/235680/Advances-in-nanobody-multimerization-and